<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401244</url>
  </required_header>
  <id_info>
    <org_study_id>GH-3939</org_study_id>
    <secondary_id>U1111-1121-3640</secondary_id>
    <nct_id>NCT01401244</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers</brief_title>
  <official_title>A Trial to Examine the Bioequivalence of Norditropin® Versus Genotropin® in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in United States of America (USA). The aim of this trial is to
      examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2011</start_date>
  <completion_date type="Actual">September 27, 2011</completion_date>
  <primary_completion_date type="Actual">September 27, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum hGH (human growth hormone) concentration-time curve</measure>
    <time_frame>from 0 to the time of the last quantifiable concentration over a 24-hour sampling period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum hGH concentration</measure>
    <time_frame>over a 24-hour sampling period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the effect (IGF-I) curve</measure>
    <time_frame>from time 0 to the time of the last concentration (AUEC0-t) over a 96-hour sampling period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum IGF-I effect (Emax)</measure>
    <time_frame>over a 96-hour sampling period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of adverse events (AE)</measure>
    <time_frame>from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of injection site reaction</measure>
    <time_frame>from the time of injection of the trial product (day 1 and 13, respectively) to follow-up during the two dosing periods (day 5 and 17, respectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal hematology laboratory parameters</measure>
    <time_frame>from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal biochemistry laboratory parameters</measure>
    <time_frame>from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal findings in physical examinations</measure>
    <time_frame>from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Genetic Disorder</condition>
  <condition>Prader-Willi Syndrome</condition>
  <condition>Growth Disorder</condition>
  <condition>Idiopathic Short Stature</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Norditropin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotropin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen</description>
    <arm_group_label>Norditropin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12</description>
    <arm_group_label>Genotropin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) 18.0-27.0 kg/m^2 (both inclusive)

          -  Considered generally healthy upon completion of medical history, physical examination,
             vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by
             the Investigator (trial physician)

        Exclusion Criteria:

          -  The receipt of any investigational medicinal product within 1 month prior to this
             trial

          -  Current or previous treatment with growth hormone or IGF-I (insulin-like growth
             factor-I)

          -  Female of childbearing potential who is pregnant, breast-feeding or intends to become
             pregnant or is not using adequate contraceptive methods (adequate contraceptive
             measures as required by local law or practice) for the duration of the trial

          -  Known presence or history of malignancy

          -  Diabetes mellitus

          -  Use of pharmacologic doses of glucocorticoids

          -  Use of anabolic steroids

          -  History of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2011</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
    <mesh_term>Dwarfism</mesh_term>
    <mesh_term>Growth Disorders</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

